Evidence map›Paper›PMID 30905360›Full record

ReviewTrends in pharmacological sciences2019

A Coordinated Attack: Rett Syndrome Therapeutic Development.

Rocco G Gogliotti, Colleen M Niswender

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in pharmacological sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Optimized Administration of the MACS chemical neuroscience · 2022
    Article
  4. Clinical and Preclinical Evidence for MNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rocco G GogliottiVanderbilt Department of Pharmacology and Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.
Colleen M NiswenderVanderbilt Department of Pharmacology and Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA; Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN, USA; Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: Colleen.niswender@vanderbilt.edu.

Funding

Development of a Selective Metabotropic Glutamate Receptor 7 Allosteric Modulator ProbeR01MH113543 · NIMH · VANDERBILT UNIVERSITY · PI LINDSLEY, CRAIG, NISWENDER, COLLEEN M · 2017 to 2019
$1.2M
Normalizing E:I imbalance in Rett Syndrome by Modulation of Late Response GenesK01MH112983 · NIMH · VANDERBILT UNIVERSITY · PI GOGLIOTTI, ROCCO GEORGE · 2017 to 2020
$543k
NIMH NIH HHS K01 MH112983NIMH NIH HHS R01 MH113543
6 · The paper itself

Abstract

Rett syndrome (RTT) is a neurodevelopmental disorder caused by mutations in the Methyl CpG binding protein 2 (MeCP2) gene. This Science & Society article focuses on pharmacological strategies that attack RTT treatment from multiple angles, including drug repurposing and de novo discovery efforts, and discusses the impacts of preclinical study design and translationally relevant outcome measures.

Indexed as

AnimalsDrug DiscoveryDrug Evaluation, PreclinicalDrug RepositioningFemaleHumansMethyl-CpG-Binding Protein 2MutationResearch DesignRett SyndromeMECP2 protein, humanMethyl-CpG-Binding Protein 2pharmacological interventionRett syndrome

Identifiers

PMID30905360
PMCPMC6482467

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.